Eli Lilly and Co

Eli Lilly and Company is a global pharmaceutical enterprise engaged in the discovery, development, and commercialization of human pharmaceutical products. Its diverse portfolio provides treatments across multiple therapeutic areas. In the field of diabetes care, the company offers a comprehensive range of insulins, such as Basaglar, various formulations of Humalog (including U-100, U-200, Mix 75/25, and Mix 50/50), insulin lispro, insulin lispro protamine, and insulin lispro mix 75/25. Additionally, its Humulin line features Humulin 70/30, Humulin N, Humulin R, and Humulin U-500. For the management of type 2 diabetes, key medications include Jardiance, Trajenta, and Trulicity. Its oncology division features medications like Alimta, utilized for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. Cyramza is indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma. Erbitux addresses colorectal cancers and various head and neck cancers, while Retevmo is prescribed for metastatic NSCLC, medullary thyroid cancer, and other thyroid cancers. Tyvyt provides treatment for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC, and Verzenio supports patients with HR+, HER2- metastatic breast cancer, node-positive breast cancer, and early breast cancer. Within immunology, Eli Lilly offers Olumiant for rheumatoid arthritis. Taltz is available as a treatment option for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. For neurological and pain management needs, the company provides Cymbalta, used for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality serves as a preventive measure for migraines and treats episodic cluster headaches. Zyprexa is prescribed for schizophrenia, bipolar I disorder, and bipolar maintenance. Beyond these core areas, Eli Lilly's product line also encompasses Bamlanivimab, etesevimab, and Bebtelovimab for COVID-19; Cialis for addressing erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company maintains strategic collaborations with numerous partners, including Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AbCellera Biologics Inc., Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Inc., Kumquat Biosciences Inc., Entos Pharmaceuticals Inc., and Foghorn Therapeutics Inc. Founded in 1876, Eli Lilly and Company's corporate headquarters are situated in Indianapolis, Indiana.